Literature DB >> 27815389

Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer.

Mo Li1,2, Qian Chen2, Xiaochun Yu3.   

Abstract

There remains great interest in practical strategies to limit the elevated risks of familial breast and ovarian cancers driven by BRCA1 mutation. Here, we report that limiting the production of reactive oxygen species (ROS) is sufficient to reduce DNA lesions and delay tumorigenesis in a murine model of BRCA1-deficient breast cancer. We documented a large amount of endogenous estrogen oxidative metabolites in the mammary gland of the model, which induced DNA adducts and apurinic/apyrimidinic sites associated with DNA double-strand breaks and genomic instability. Repressing estrogen oxidation via antioxidant treatments reduced oxidative DNA lesions and delayed the onset of mammary tumors. Overall our work suggests an answer to the long-standing question of why germline BRCA1 mutations cause tissue-specific tumors, in showing how tissue-specific, ROS-induced DNA lesions create a nongenetic force to promote mammary tumors in BRCA1-deficient mice. Our findings create a rationale for evaluating suitable antioxidant modalities as a chemopreventive strategy for familial breast cancer. Cancer Res; 77(2); 448-58. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27815389      PMCID: PMC5596625          DOI: 10.1158/0008-5472.CAN-16-2350

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Cell cycle checkpoint signaling through the ATM and ATR kinases.

Authors:  R T Abraham
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

2.  The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity.

Authors:  Muhammad Zahid; Ekta Kohli; Muhammad Saeed; Eleanor Rogan; Ercole Cavalieri
Journal:  Chem Res Toxicol       Date:  2006-01       Impact factor: 3.739

Review 3.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

Authors:  P T Männistö; S Kaakkola
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

4.  Estrogen metabolism and risk of breast cancer in postmenopausal women.

Authors:  Barbara J Fuhrman; Catherine Schairer; Mitchell H Gail; Jennifer Boyd-Morin; Xia Xu; Laura Y Sue; Saundra S Buys; Claudine Isaacs; Larry K Keefer; Timothy D Veenstra; Christine D Berg; Robert N Hoover; Regina G Ziegler
Journal:  J Natl Cancer Inst       Date:  2012-01-09       Impact factor: 13.506

Review 5.  Estrogens, BRCA1, and breast cancer.

Authors:  L Hilakivi-Clarke
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

Review 6.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

Review 7.  Estrogens and epithelial ovarian cancer.

Authors:  Séverine Cunat; Pascale Hoffmann; Pascal Pujol
Journal:  Gynecol Oncol       Date:  2004-07       Impact factor: 5.482

8.  The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.

Authors:  Reena Shakya; Matthias Szabolcs; Ellen McCarthy; Elson Ospina; Katia Basso; Subhadra Nandula; Vundavalli Murty; Richard Baer; Thomas Ludwig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

9.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

Review 10.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

View more
  6 in total

1.  Inhibiting reactive oxygen species-dependent autophagy enhanced baicalein-induced apoptosis in oral squamous cell carcinoma.

Authors:  Bo Li; Mei Lu; Xin-Xiang Jiang; Meng-Xiong Pan; Jun-Wu Mao; Mei Chen
Journal:  J Nat Med       Date:  2017-02-07       Impact factor: 2.343

2.  Tissue specificity of DNA damage response and tumorigenesis.

Authors:  Siman Sun; Michael D Osterman; Mo Li
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

Review 3.  Emerging Perspective: Role of Increased ROS and Redox Imbalance in Skin Carcinogenesis.

Authors:  Dehai Xian; Rui Lai; Jing Song; Xia Xiong; Jianqiao Zhong
Journal:  Oxid Med Cell Longev       Date:  2019-09-16       Impact factor: 6.543

Review 4.  Evolving insights: how DNA repair pathways impact cancer evolution.

Authors:  Jiadong Zhou; Xiao Albert Zhou; Ning Zhang; Jiadong Wang
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

Review 5.  Possible Beneficial Effects of N-Acetylcysteine for Treatment of Triple-Negative Breast Cancer.

Authors:  Youngjoo Kwon
Journal:  Antioxidants (Basel)       Date:  2021-01-24

6.  The histone demethylase PHF8 regulates TGFβ signaling and promotes melanoma metastasis.

Authors:  Rana S Moubarak; Ana de Pablos-Aragoneses; Vanessa Ortiz-Barahona; Yixiao Gong; Michael Gowen; Igor Dolgalev; Sorin A A Shadaloey; Diana Argibay; Alcida Karz; Richard Von Itter; Eleazar Carmelo Vega-Sáenz de Miera; Elena Sokolova; Farbod Darvishian; Aristotelis Tsirigos; Iman Osman; Eva Hernando
Journal:  Sci Adv       Date:  2022-02-18       Impact factor: 14.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.